非薬物療法で心不全をコントロールして癒す

出版社： 文光堂
著者：
発行日： 2017-05-15
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784830619373
電子書籍版： 2017-05-15 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

心不全は複雑な病態ゆえに，治療法も多岐におよぶ中，残念ながら，これまで多分野の非薬物療法だけを扱う書籍は多くない．そこで本書では，非薬物療法を有機的かつ効率的に学べるよう，コンパクトにまとめることにした．現在までにエビデンスが確立された治療法も今後発展が期待される治療法もあるが，現在どこまで効果が確認され，どのような症例に効果が期待できるのか，そして今後解決すべき課題や発展性についてもすべてがわかる1冊．

目次

  • 非薬物療法で心不全をコントロールして癒す

    ―目次―

    I　総　論−非薬物療法−

    II　心臓を再同期させる
    　1　心不全における心臓非再同期を識り，評価する
    　2　心臓再同期療法を期待できる病態とは？
    　3　心臓再同期療法に残された課題と展望

    III　不整脈をコントロールする
    　1　心不全における心房細動とその治療法
    　2　心不全における心室不整脈治療
    　3　心不全における突然死と植込み型除細動器デバイスの
    　　　　効果と課題

    IV　心室リモデリングへの対応
    　1　心不全における虚血性心疾患と血行再建の適応
    　2　機能性（虚血性）僧帽弁逆流の病態と評価方法
    　3　僧帽弁形成術ならびに左室形成術について
    　4　MitraClipの現状 大野洋平

    V　自律神経をコントロールする
    　1　心不全に対する陽圧換気療法の適応と効果
    　2　和温療法
    　3　迷走神経刺激
    　4　腎交感神経デナベーション

    VI　再生医療に期待する
    　1　iPS細胞を用いた再生心筋細胞移植
    　2　重症心不全に対する細胞シート移植の現状と展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論 - 非薬物療法 -

P.7 掲載の参考文献
1) The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 ; 316 : 1429-1435
 
2) The SOLVD Investigattors : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992 ; 327 : 685-691
 
3) CIBIS-II Investigators and Committees : The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 1999 ; 353 : 9-13
 
4) Packer, M et al : Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 ; 344 : 1651-1658
 
5) Pitt, B et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 ; 341 : 709-717
 
6) Bardy, GH et al : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237
 
7) Cleland, JG et al : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 ; 352 : 1539-1549
 
8) Bristow, MR et al : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 ; 350 : 2140-2150
 
9) Braunwald, E : Shattuck lecture--cardiovascular medicine at the turn of the millennium : triumphs, concerns, and opportunities. N Engl J Med 1997 ; 337 : 1360-1369
 
10) Ogawa, S et al : Optimal treatment strategy for patients with paroxysmal atrial fibrillation : JRHYTHM Study. Circ J 2009 ; 73 : 242-248
 
11) Kotecha, D et al : Efficacy of β blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis. Lancet 2014 ; 384 : 2235-2243
 
12) Yancy, CW et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 ; 128 : e240-e327
 
13) Machino-Ohtsuka, T et al : Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol 2013 ; 62 : 1857-1865
 
14) Zakeri, R et al : Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction : a community-based study. Circulation 2013 ; 128 : 1085-1093
 
15) 日本循環器学会 : 循環器疾患診療実態調査2016年報告書 http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2015web.pdf
 
16) Floras, JS : Sympathetic nervous system activation in human heart failure : clinical implications of an updated model. J Am Coll Cardiol 2009 ; 54 : 375-385
 
17) Takahashi, K et al : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006 ; 126 : 663-676
 

II 心臓を再同期させる

P.17 掲載の参考文献
1) Kashani, A et al : Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005 ; 46 : 2183-2192
 
2) Oyenuga, O et al : Usefulness of echocardiographic dyssynchrony in patients with borderline QRS duration to assist with selection for cardiac resynchronization therapy. JACC Cardiovasc Imaging 2010 ; 3 : 132-140
 
3) Tanaka, H et al : Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy : results of the Speckle Tracking and Resynchronization (STAR) study. Eur Heart J 2010 ; 31 : 1690-1700
 
4) Maruo, T et al : The Speckle Tracking Imaging for the Assessment of Cardiac Resynchronization Therapy (START) study. Circ J 2015 ; 79 : 613-622
 
5) Gorcsan, J, 3rd et al : Echocardiography for cardiac resynchronization therapy : recommendations for performance and reporting--a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr 2008 ; 21 : 191-213
 
6) Spragg, DD et al : Regional alterations in protein expression in the dyssynchronous failing heart. Circulation 2003 ; 108 : 929-932
 
7) Vernooy, K et al : Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J 2005 ; 26 : 91-98
 
8) Ogano, M et al : Cardiac resynchronization therapy restored ventricular septal myocardial perfusion and enhanced ventricular remodeling in patients with nonischemic cardiomyopathy presenting with left bundle branch block. Heart Rhythm 2014 ; 11 : 836-841
 
9) Risum, N et al : Identification of typical left bundle branch block contraction by strain echocardiography is additive to electrocardiography in prediction of long-term outcome after cardiac resynchronization therapy. J Am Coll Cardiol 2015 ; 66 : 631-641
 
10) Shenkman, HJ et al : Congestive heart failure and QRS duration : establishing prognosis study. Chest 2002 ; 122 : 528-534
 
11) Sandhu, R et al : Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. Am J Cardiol 2004 ; 93 : 244-246
 
12) Tanaka, H et al : Left ventricular mechanical dyssynchrony in acute onset cardiomyopathy : association of its resolution with improvements in ventricular function. JACC Cardiovasc Imaging 2011 ; 4 : 445-456
 
13) Tanaka, H et al : Effect of left ventricular dyssynchrony on cardiac sympathetic activity in heart failure patients with wide QRS duration. Circ J 2012 ; 76 : 382-389
 
14) Matsumoto, K et al : Relation between left ventricular morphology and reduction in functional mitral regurgitation by cardiac resynchronization therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2011 ; 108 : 1327-1334
 
15) Sitges, M et al : Long-term effect of cardiac resynchronization therapy on functional mitral valve regurgitation. Am J Cardiol 2009 ; 104 : 383-388
 
16) Bruch, C et al : Left bundle branch block in chronic heart failure-impact on diastolic function, filling pressures, and B-type natriuretic peptide levels. J Am Soc Echocardiogr 2006 ; 19 : 95-101
 
17) Yu, CM et al : Improvement of atrial function and atrial reverse remodeling after cardiac resynchronization therapy for heart failure. J Am Coll Cardiol 2007 ; 50 : 778-785
 
18) Bleeker, GB et al : Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol 2005 ; 46 : 2264-2269
 
19) Baldasseroni, S et al : Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure : a report from the Italian network on congestive heart failure. Am Heart J 2002 ; 143 : 398-405
 
20) Desai, AD et al : Prognostic significance of quantitative QRS duration. Am J Med 2006 ; 119 : 600-606
 
21) Ruschitzka, F et al : Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013 ; 369 : 1395-1405
 
P.23 掲載の参考文献
1) Cleland, JG et al : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 ; 352 : 1539-1549
 
2) Carson, P et al : Mode of death in advanced heart failure : the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005 ; 46 : 2329-2334
 
3) Tang, AS et al : Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010 ; 363 : 2385-2395
 
4) Chung, ES et al : Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008 ; 117 : 2608-2616
 
5) Healey, JS et al : Cardiac resynchronization therapy in patients with permanent atrial fibrillation : results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2012 ; 5 : 566-570
 
6) Brignole, M et al : 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy : the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013 ; 34 : 2281-2329
 
7) Dickstein, K et al : The European cardiac resynchronization therapy survey. Eur Heart J 2009 ; 30 : 2450-2460
 
8) Singh, JP et al : Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011 ; 123 : 1159-1166
 
9) Gold, MR et al : The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J 2011 ; 32 : 2516-2524
 
10) Martin, DO et al : Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy : results of the adaptive CRT trial. Heart Rhythm 2012 ; 9 : 1807-1814
 
11) Daubert, JC et al : 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure : implant and follow-up recommendations and management. Europace 2012 ; 14 : 1236-1286
 
12) Mullens, W et al : Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 2009 ; 53 : 765-773
 
13) Hindricks, G et al : Implant-based multiparameter telemonitoring of patients with heart failure (INTIME) : a randomised controlled trial. Lancet 2014 ; 384 : 583-590
 
14) Pappone, C et al : Improving cardiac resynchronization therapy response with multipoint left ventricular pacing : Twelve-month follow-up study. Heart Rhythm 2015 ; 12 : 1250-1258
 
P.32 掲載の参考文献
1) 日本循環器学会, 他 : 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告. 不整脈の非薬物治療ガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_okumura_h.pdf (2016年10月閲覧)
 
2) Cleland, JG et al : The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005 ; 352 : 1539-1549
 
3) Lindenfeld, J et al : Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007 ; 115 : 204-212
 
4) Moss, AJ et al : Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009 ; 361 : 1329-1338
 
5) Tang, AS et al : Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010 ; 363 : 2385-2395
 
6) Beshai, JF et al : Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007 ; 357 : 2461-2471
 
7) Ruschitzka, F et al : Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013 ; 369 : 1395-1405
 
8) Strauss, DG et al : ECG quantification of myocardial scar in cardiomyopathy patients with or without conduction defects : correlation with cardiac magnetic resonance and arrhythmogenesis. Circ Arrhythm Electrophysiol 2008 ; 1 : 327-336
 
9) Singh, JP et al : Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011 ; 123 : 1159-1166
 
10) Khan, FZ et al : Targeted left ventricular lead placement to guide cardiac resynchronization therapy : the TARGET study : a randomized, controlled trial. J Am Coll Cardiol 2012 ; 59 : 1509-1518
 
11) Mullens, W et al : Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 2009 ; 53 : 765-773
 
12) Auricchio, A et al : Effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure. The Pacing Therapies for Congestive Heart Failure Study Group. The Guidant Congestive Heart Failure Research Group. Circulation 1999 ; 99 : 2993-3001
 
13) Ellenbogen, KA et al : Primary results from the SmartDelay determined AV optimization : a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial : a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010 ; 122 : 2660-2668
 
14) Martin, DO et al : Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy : results of the adaptive CRT trial. Heart Rhythm 2012 ; 9 : 1807-1814
 
15) Yu, CM et al : Intrathoracic impedance monitoring in patients with heart failure : correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005 ; 112 : 841-848
 
16) Conraads, VM et al : Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations : the SENSE-HF trial. Eur Heart J 2011 ; 32 : 2266-2273
 
17) van Veldhuisen, DJ et al : Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011 ; 124 : 1719-1726
 
18) Whellan, DJ et al : Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations : results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol 2010 ; 55 : 1803-1810
 
19) Abraham, WT et al : Wireless pulmonary artery haemodynamic monitoring in chronic heart failure : a randomised controlled trial. Lancet 2011 ; 377 : 658-666
 
20) Ritzema, J et al : Physician-directed patient selfmanagement of left atrial pressure in advanced chronic heart failure. Circulation 2010 ; 121 : 1086-1895
 

III 不整脈をコントロールする

P.38 掲載の参考文献
1) Stevenson, WG et al : Atrial fibrillation in heart failure. N Engl J Med 1999 ; 341 : 910-911
 
2) Ehrlich, JR et al : Atrial fibrillation and congestive heart failure : specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002 ; 13 : 399-405
 
3) Benjamin, EJ et al : Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 ; 271 : 840-844
 
4) Maisel, WH et al : Atrial fibrillation in heart failure : epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003 ; 91 : 2D-8D
 
5) Saksena, S et al : (eds) : Electrophysiological disorder of the heart. Elsevier Churchill-Livingstone, 2005, 283-363
 
6) Packer, DL et al : Tachycardia-induced cardiomyopathy : a reversible form of left ventricular dysfunction. Am J Cardiol 1986 ; 57 : 563-570
 
7) 日本循環器学会. 循環器病ガイドラインシリーズ 2013年版 : 心房細動治療 (薬物) ガイドライン (2013年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf (2017年5月閲覧)
 
8) European Heart Rhythm Association : Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010 ; 31 : 2369-2429
 
9) Wyse, DG et al : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 ; 347 : 1825-1833
 
10) Roy, D et al : Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 ; 358 : 2667-2677
 
11) Jais, P et al : Catheter ablation versus antiarrhythmic drugs for atrial fibrillation : the A4 study. Circulation 2008 ; 118 : 2498-2505
 
12) Parkash, R et al : Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation : a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 2011 ; 22 : 729-738
 
13) Hsu, LF et al : Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 ; 351 : 2373-2383
 
14) Khan, MN et al : Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008 ; 359 : 1778-1785
 
15) Di Biase, L et al : Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device : results from the AATAC Multicenter Randomized Trial. Circulation 2016 ; 133 : 1637-1644
 
16) Al Halabi, S et al : Catheter ablation for atrial fibrillation in heart failure patients : a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol 2015 ; 1 : 200-209
 
P.47 掲載の参考文献
1) Stevenson, WG et al : Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction. Circulation 1993 ; 88 (4 Pt 1) : 1647-1670
 
2) Sapp, JL et al : Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016 ; 375 : 111-121
 
3) de Chillou, C et al : Isthmus characteristics of reentrant ventricular tachycardia after myocardial infarction. Circulation 2002 ; 105 : 726-731
 
4) Soejima, K et al : Catheter ablation in patients with multiple and unstable ventricular tachycardias after myocardial infarction : short ablation lines guided by reentry circuit isthmuses and sinus rhythm mapping. Circulation 2001 ; 104 : 664-669
 
5) Bai, R et al : Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy : arrhythmia-free survival after endoepicardial substrate based mapping and ablation. Circ Arrhythm Electrophysiol 2011 ; 4 : 478-485
 
6) Oza, S et al : Substrate-based endocardial ablation of postinfarction ventricular tachycardia. Heart Rhythm 2006 ; 3 : 607-609
 
7) Di Biase, L et al : Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2012 ; 60 : 132-141
 
8) Yoshida, K et al : Feasibility of targeting catheter ablation to the markedly low-voltage area surrounding infarct scars in patients with post-infarction ventricular tachycardia. Circ J 2008 ; 72 : 1112-1119
 
9) Tokuda, M et al : Catheter ablation of ventricular tachycardia in nonischemic heart disease. Circ Arrhythm Electrophysiol 2012 ; 5 : 992-1000
 
10) Katz, DF et al : Safety of ventricular tachycardia ablation in clinical practice : findings from 9699 hospital discharge records. Circ Arrhythm Electrophysiol 2015 ; 8 : 362-370
 
P.52 掲載の参考文献
1) Moss, AJ et al : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 ; 346 : 877-883
 
2) Kadish, A et al : Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 ; 350 : 2151-2158
 
3) Bardy, GH et al : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 ; 352 : 225-237
 
4) Satake, H et al : Current status of primary prevention of sudden cardiac death with implantable car dioverter defibrillator in patients with chronic heart failure--a report from the CHART-2 Study. Circ J 2015 ; 79 : 381-390
 
5) Hohnloser, SH et al : Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004 ; 351 : 2481-2488
 
6) Kutyifa, V et al : Use of the wearable cardioverter defibrillator in high-risk cardiac patients : data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015 ; 132 : 1613-1619
 
7) Piccini, JP Sr et al : Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death : a science advisory from the American Heart Association. Circulation 2016 ; 133 : 1715-1727
 
8) Boersma, L et al : Performance of the subcutaneous implantable defibrillator in primary prevention patients with and without a reduced ejection fraction versus secondary prevention patients. Heart Rhythm 2016 Nov 24. pii : S1547-5271 (16) 31070-0 [Epub ahead of print]
 

IV 心室リモデリングへの対応

P.63 掲載の参考文献
1) Gheorghiade, M et al : Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006 ; 114 : 1202-1213
 
2) Tsutsui, H et al : Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 2007 ; 71 : 449-454
 
3) The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 ; 325 : 293-302
 
4) Steg, PG et al : Determinants and prognostic impact of heart failure complicating acute coronary syndromes : observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004 ; 109 : 494-499
 
5) Uretsky, BF et al : Acute coronary findings at autopsy in heart failure patients with sudden death : results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000 ; 102 : 611-616
 
6) Ishihara, M et al : Thirty years trend in acute myocardial infarction during coronary angiography at a tertiary emergency center in Japan. J Cardiol 2012 ; 59 : 243-248
 
7) Afridi, I et al : Serial changes in response of hibernating myocardium to inotropic stimulation after revascularization : a dobutamine echocardiographic study. J Am Coll Cardiol 1997 ; 30 : 1233-1240
 
8) Kiat, H et al : Late reversibility of tomographic myocardial thallium-201 defects : an accurate marker of myocardial viability. J Am Coll Cardiol 1988 ; 12 : 1456-1463
 
9) Allman, KC et al : Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction : a meta-analysis. J Am Coll Cardiol 2002 ; 39 : 1151-1158
 
10) Velazquez, EJ et al : Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011 ; 364 : 1607-1616
 
11) Velazquez, EJ et al : Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016 ; 374 : 1511-1520
 
12) Bonow, RO et al : Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011 ; 364 : 1617-1625
 
13) Farkouh, ME et al : Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012 ; 367 : 2375-2384
 
14) Mohr, FW et al : Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013 ; 381 : 629-638
 
15) Windecker, S et al : 2014 ESC/EACTS Guidelines on myocardial revascularization : The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014 ; 35 : 2541-2619
 
P.69 掲載の参考文献
1) Grigioni, F et al : Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol 2005 ; 45 : 260-267
 
2) Bursi, F et al : Mitral regurgitation after myocardial infarction : a review. Am J Med 2006 ; 119 : 103-112
 
3) Kaul, S et al : Mechanism of ischemic mitral regurgitation. An experimental evaluation. Circulation 1991 ; 84 : 2167-2180
 
4) Watanabe, N et al : Dynamics of mitral complex geometry and functional mitral regurgitation during heart failure treatment-real-time three-dimensional echocardiographic study. J Echocardiogr 2006 ; 4 : 51-58
 
5) Toida, R et al : Prognostic implication of three-dimensional mitral valve tenting geometry in dilated cardiomyopathy. J Heart Valve Dis 2015 ; 24 : 577-585
 
6) Nishino, S et al : The course of ischemic mitral regurgitation in acute myocardial infarction after primary percutaneous coronary intervention : from emergency room to long-term follow-up. Circ Cardiovasc Imaging 2016 ; 9 : e004841
 
P.79 掲載の参考文献
1) Franco-Cereceda, A et al : Partial left ventriculectomy for dilated cardiomyopathy : is this an alternative to transplantation? J Thorac Cardiovasc Surg 2001 ; 121 : 879-893
 
2) Otsuji, Y et al : Insights from three-dimentional echocardiography into the mechanism of functional mitral regurgitation : direct in vivo demonstration of altered leaflet tethering geometry. Circulation 1997 ; 96 : 1999-2008
 
3) Frater, RW : The effects on cordal and leaflet stiffness of severe apical, posterior, and outward papillary displacement in advanced ventricular mechanism heart failure and mitral insufficiency. J Heart Valve Dis 2011 ; 20 : 608-618
 
4) Nishimura, RA et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014 ; 63 : e57-185
 
5) Shingu Y, Matsui Y : Did we misunderstand how to calculate total stroke work in mitral regurgitation by echocardiography? Circ J 2012 ; 76 : 1533-1534
 
6) 日本循環器学会 : 循環器病ガイドラインシリーズ 2012年版. 弁膜疾患の非薬物治療に関するガイドライン (2012年改訂版) http://www.j-circ.or.jp/guideline/pdf/JSC2012_ookita_h.pdf (2017年3月閲覧)
 
7) Lancelloti, P et al : Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 2003 ; 108 : 1713-1717
 
8) Bolling, SF et al : Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 1998 ; 115 : 381-386
 
9) Magne, J et al : Ischemic mitral regurgitation : a complex multifaceted disease. Cardiology 2009 ; 112 : 244-259
 
10) Magne, J et al : Restrictive annuloplasty for ischemic mitral regurgitation may induce functional mitral stenosis. J Am Coll Cardiol 2008 ; 51 : 1692-1701
 
11) Borger, MA et al : Initial results of the chordalcutting operation for ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2007 ; 133 : 1483-1492
 
12) Kincaid, EH et al : Anterior leaflet augmentation for ischemic mitral regurgitation. Ann Thorac Surg 2004 ; 78 : 564-568
PubMed
13) De Bonis, M et al : Mitral valve repair for functional mitral regurgitation in end-stage dilated cardiomyopathy : role of the "edge-to-edge" technique. Circulation 2005 ; 112 (Suppl) : 1-402-1408
 
14) Croft, LR et al : Efficacy of the edge-to-edge repair in the setting of a dilated ventricle : an in vitro study. Ann Thoac Surg 2007 ; 84 : 1578-1584
 
15) Mihosa, CG, Santanab O : Is an adjunctive subvalvular repair during mitral annuloplasty for secondary mitral regurgitation effective in preventing recurrent regurgitation? Interact Cardiovasc Thorac Sug 2016 ; 22 : 216-221
 
16) Braun, J et al : Restrictive mitral annuloplasty cures ischemic mitral regurgitation and heart failure. Ann Thorac Surg 2008 ; 85 : 430-437
 
17) Matsui Y : Overlapping left ventricular restoration. Circ J 2009 ; 73 (Suppl A) : A13-A18
 
18) Hvass U, Joudinaud T : The papillary muscle sling for ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2010 ; 139 : 418-423
 
19) Kron, IL et al : Surgical relocation of the posterior papillary muscle in chronic ischemic mitral regurgitation. Ann Thorac Surg 2002 ; 74 : 600-601
 
20) Watanabe, T et al : Influence of procedural differences on mitral valve configuration after surgical repair for functional mitral regurgitation : in which direction should the papillary muscle be relocated? J Cardiothorac Surg 2014 ; 9 : 185
PubMed
21) Komeda, M et al : "Papillary heads optimization" for more geometric repair of functional mitral regurgitation toward ventricular treatment. Ann Cardiothorac Surg 2015 ; 4 : 393-396
 
22) Jorapur, V et al : Quantification of annular dilatation and papillary muscle separation in functional mitral regurgitation : role of anterior mitral leaflet length as reference. Echocardiography 2005 ; 22 : 465-472
 
23) Menicanti, L et al : Ischemic mitral regurgitation : intraventricular papillary muscle imbrication without mitral ring during left ventricular restoration. J Thorac Cardiovasc Surg 2002 ; 123 : 1041-1050
 
24) Matsui, Y et al : Overlapping cardiac volume reduction operation. J Thorac Cardiovasc Surg 2002 ; 124 : 395-397
 
25) Matsui, Y et al : Integrated overlapping ventriculoplasty combined with papillary muscle placation for severely dilated heart failure. J Thorac Cardiovasc Surg 2004 ; 127 : 1221-1223
 
26) Wakasa, S et al : The extent of papillary muscle approximation affects mortality and durability of mitral valve repair for ischemic mitral regurgitation. J Cardiothorac Surg 2014 ; 9 : 98
PubMed
27) Wakasa, S et al : Surgical strategy for ischemic mitral regurgitation adopting subvalvular and ventricular procedures. Ann Thorac Cardiovasc Surg.
PubMed
28) Shingu Y, Matsui Y : How can we prevent functional mitral stenosis after surgery? J Thorac Cardiovasc Surg 2010 ; 140 : 251-252
 
29) Vassileva, CM et al : Meta-analysis of short-term and long-term survival following repair versus replacement for ischemic mitral regurgitation. Eur J Cardiothorac Surg 2011 ; 39 : 295-303
 
30) Goldstein, D et al : Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med 2016 ; 374 : 344-353
 
31) Shingu, Y et al : Slope in preload recruitable stroke work relationship predicts survival after left ventriculoplasty and mitral repair in patients with idiopathic cardiomyopathy. J Cardiol 2015 ; 65 : 157-163
 
32) Warwick, R et al : Mathematical modelling to identify patients who should not undergo left ventricle remodelling surgery. Interact Cardiovasc Thorac Surg 2010 ; 10 : 661-665
 
33) Calafiore, AM et al : Left ventricular surgical restoration fort anteroseptal scars : volume versus shape. J Thora Cardiovasc Surg 2010 ; 139 : 1123-1130
 
34) Dor, V et al : Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction : comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998 ; 116 : 50-59
 
35) Isomura, T et al : Septal anterior ventricular exclusion operation (Pacopexy) for ischemic dilated cardiomyopathy : treat form not disease. Eur J Cardiothoac Surg 2006 ; 29 (Suppl) 1 : S245-250
PubMed
36) Hunt, SA et al : 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines : developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 ; 119 : e391-e479
 
37) 循環器病の診断と治療に関するガイドライン (2005-2005年度合同研究班報告) : 虚血性心疾患に対するバイパスグラフトと手術術式の選択ガイドライン. Cir J 2006 ; 70 (Suppl IV) : 1564
 
38) Jones, RH et al : Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009 ; 360 : 1705-1717
 
39) Buckberg GD, Athanasuleas CL : The STICH trial : misguided conclusions. J Thorac Cardiovasc Surg 2009 ; 138 : 1060-1064
 
40) Wakasa, S et al : Risk scores for predicting mortality after surgical ventricular reconstruction for ischemic cardiomyopathy : results of a Japanese multicenter study. J Thorac Cardiovasc Surg 2014 ; 147 : 1868-1874
 
41) Batista, RJ et al : Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Card Surg 1996 ; 11 : 96-97
 
42) Suma, H et al : Selected ventriculoplasty for idiopathic dilated cardiomyopathy with advanced congestive heart failure : midterm results and risk analysis. Eur J Cardiothorac Surg 2007 ; 32 : 912-916
 
P.86 掲載の参考文献
1) Alfieri, O et al : The double-orifice technique in mitral valve repair : a simple solution for complex problems. J Thorac Cardiovasc Surg 2001 ; 122 : 674-681
 
2) Ohno, Y et al : Acute left atrial spontaneous echocardiographic contrast and suspicious thrombus formation following mitral regurgitation reduction with the MitraClip system. JACC Cardiovasc Interv 2014 ; 7 : 1322-1323
 
3) Nishimura, RA et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014 ; 63 : 2438-2488
 
4) Ohno, Y et al : Impact of chronic kidney disease on outcomes after percutaneous mitral valve repair with the MitraClip system : insights from the GRASP registry. EuroIntervention 2016 ; 11 : e1649-e1657
 
5) Lubos, E et al : MitraClip therapy in surgical highrisk patients : identification of echocardiographic variables affecting acute procedural outcome. JACC Cardiovasc Interv 2014 ; 7 : 394-402
 
6) Ohno, Y et al : Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System : 30-day and 12-month follow-up from the GRASP Registry. Eur Heart J Cardiovasc Imaging 2014 ; 15 : 1246-1255
 

V 自律神経をコントロールする

P.91 掲載の参考文献
1) Javaheri, S et al : Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol 2007 ; 49 : 2028-2034
 
2) Wang, H et al : Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007 ; 49 : 1625-1631
 
3) Kasai, T et al : Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest 2008 ; 133 : 690-696
 
4) Momomura, S et al : Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J 2015 ; 79 : 981-990
 
5) Arzt, M et al : Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure : a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007 ; 115 : 3173-3180
 
6) Oldenburg, O et al : Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration. Eur J Heart Fail 2008 ; 10 : 581-586
 
7) Momomura, S et al : Adaptive servo-ventilation therapy using an innovative ventilator for patients with chronic heart failure : a real-world, multicenter, retrospective, observational study (SAVIOR-R). Heart Vessels 2015 ; 30 : 805-817
 
8) Cowie, MR et al : Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015 ; 373 : 1095-1105
 
P.100 掲載の参考文献
1) Tei, C : Waon therapy : soothing warmth therapy. J Cardiol 2007 ; 49 : 301-304
 
2) Tei, C et al : Acute hemodynamic improvement by thermal vasodilation in congestive heart failure. Circulation 1995 ; 91 : 2582-2590
 
3) 鄭忠和 : 和温療法 (日本で開発された治療法). 循環器専門医 2014 ; 22 : 123-130
 
4) Tei, C et al : Waon therapy for managing chronic heart failure-results from a multicenter prospective randomized WAON-CHF Study. Circ J 2016 ; 80 : 827-834
 
5) Kihara, T et al : Waon therapy improves the prognosis of patients with chronic heart failure. J Cardiol 2009 : 53 : 214-218
 
6) Miyata, M et al : Beneficial effects of Waon therapy on patients with chronic heart failure : results of a prospective multicenter study. J Cardiol 2008 ; 52 : 79-85
 
7) Tei, C et al : Waon therapy improves peripheral arterial disease. J Am Coll Cardiol 2007 ; 50 : 2169-2171
 
8) Imamura, M et al : Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. J Am Coll Cardiol 2001 ; 38 : 1083-1088
 
9) Kihara, T et al : Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol 2002 ; 39 : 754-759
 
10) Ikeda, Y et al : Repeated sauna therapy increases arterial endothelial nitric oxide synthase expression and nitric oxide production in cardiomyopathic hamsters. Circ J 2005 ; 69 : 722-729
 
11) Ikeda, Y et al : Effect of repeated sauna therapy on survival in TO-2 cardiomyopathic hamsters with heart failure. Am J Cardiol 2002 ; 90 : 343-345
 
12) Akasaki, Y et al : Repeated thermal therapy upregulates endothelial nitric oxide synthase and augments angiogenesis in a mouse model of hindlimb ischemia. Circ J 2006 ; 70 : 463-470
 
13) Miyauchi, T et al : Waon therapy upregulates Hsp90 and leads to angiogenesis through the Aktendothelial nitric oxide synthase pathway in mouse hindlimb ischemia. Circ J 2012 ; 76 : 1712-1721
 
14) Kuwahata, S et al : Improvement of autonomic nervous activity by Waon therapy in patients with chronic heart failure. J Cardiol 2011 ; 57 : 100-106
 
15) Fujita, S et al : Effect of Waon therapy on oxidative stress in chronic heart failure. Circ J 2011 ; 75 : 348-356
 
P.106 掲載の参考文献
1) Olshansky, B et al : Parasympathetic nervous system and heart failure : pathophysiology and potential implications for therapy. Circulation 2008 ; 118 : 863-871
 
2) Sandercock, GR et al : The role of heart rate variability in prognosis for different modes of death in chronic heart failure. Pacing Clin Electrophysiol 2006 ; 29 : 892-904
 
3) Li, W et al : Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev 2011 ; 16 : 137-145
 
4) Brack, KE et al : Direct evidence of nitric oxide release from neuronal nictric oxide synthase activation in the left ventride as a result of cervical vagus nerve stimulation. J Physiol 2009 ; 587 : 3045-3054
 
5) Li, M et al : Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004 ; 109 : 120-124
 
6) Sabbah, HN et al : Vagus nerve stimulation in experimental heart failure. Heart Fail Rev 2011 ; 16 : 171-178
 
7) Zhang, Y et al : Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009 ; 2 : 692-699
 
8) Gold, MR et al : Vagus nerve stimulation for the treatment of heart failure : The INOVATE-HF trial. J Am Coll Cardiol 2016 ; 68 : 149-158
 
9) Zannad, F et al : Chronic vagal stimulation for the treatment of low ejection fraction heart failure : results of the neural cardiac therapy for heart failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015 ; 36 : 425-433
 
10) Premchand, RK et al : Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure : results of the ANTHEM-HF trial. J Cardiac Fail 2014 ; 20 : 808-816
 
P.112 掲載の参考文献
1) Booth, LC et al : The role of renal afferent and efferent nerve fibers in heart failure. Front Physiol 2015 ; 6 : 270
PubMed
2) Krum, H et al : Percutaneous renal denervation in patients with treatment-resistant hypertension : final 3-year report of the Symplicity HTN-1 study. Lancet 2014 ; 383 : 622-629
 
3) Krum, H et al : Catheter-based renal sympathetic denervation for resistant hypertension : a multicentre safety and proof-of-principle cohort study. Lancet 2009 ; 373 : 1275-1281
 
4) Symplicity HTN-2 Investigators : Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial) : a randomised controlled trial. Lancet 2010 ; 376 : 1903-1909
 
5) Bhatt, DL et al : A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 ; 370 : 1393-1401
 
6) Kario, K et al : SYMPLICITY HTN-Japan-First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients. Circ J 2015 ; 79 : 1222-1229
 
7) Desch, S et al : Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015 ; 65 : 1202-1208
 
8) Davies, JE et al : First-in-man safety evaluation of renal denervation for chronic systolic heart failure : primary outcome from REACH-Pilot study. Int J Cardiol 2013 ; 162 : 189-192
 
9) Schirmer, SH et al : Improvements in left ventricular hypertrophy and diastolic function following renal denervation : effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol 2014 ; 63 : 1916-1923
 
10) Krum, J et al : The SYMPLICITY HF Feasibility Study : Twelve month outcomes of renal denervation in patients with chronic heart failure and renal impairment (AHA 2015) Circulation 2015 ; 132 : A10452
 
11) Pokushalov, E et al : A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012 ; 60 : 1163-1170
 
12) Linz, D et al : Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension 2013 62 : 767-774
 
13) Witikowskii, A et al : Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011 ; 58 : 559-565
 
14) Kario, K et al : Impact of renal denervation on patients with obstructive sleep apnea and Resistant Hypertension-Insights From the SYMPLICITY HTN-3 Trial. Circ J 2016 ; 80 : 1404-1412
PubMed

VI 再生医療に期待する

P.119 掲載の参考文献
1) Seki, T et al : Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc 2012 ; 7 : 718-728
 
2) Rao, J et al : Stepwise clearance of repressive roadblocks drives cardiac induction in human ESCs, Cell Stem Cell 2016 ; 18 : 341-353
 
3) Hattori, F et al : Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2010 ; 7 : 61-66
 
4) Tohyama, S et al : Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013 ; 12 : 127-137
 
5) Hemmi, N et al : A massive suspension culture system with metabolic purification for human pluripotent stem cell-derived cardiomyocytes. Stem Cells Transl Med 2014 ; 3 : 1473-1483
 
P.123 掲載の参考文献
1) Shimizu, T et al : Two-dimensional manipulation of cardiac myocyte sheets utilizing temperature-responsive culture dishes augments the pulsatile amplitude. Tissue Eng 2001 ; 7 : 141-151
 
2) Shimizu, T et al : Electrically communicating three-dimensional cardiac tissue mimic fabricated by layered cultured cardiomyocyte sheets. J Biomed Mater Res 2002 ; 60 : 110-117
 
3) Memon, IA et al : Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg 2005 ; 130 : 1333-1341
 
4) Kondoh, H et al : Reorganization of cytoskeletal proteins and prolonged life expectancy caused by hepatocyte growth factor in a hamster model of late-phase dilated cardiomyopathy. J Thorac Cardiovasc Surg 2005 ; 130 : 295-302
 
5) Hata, H et al : Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model. J Thorac Cardiovasc Surg 2006 ; 132 : 918-924
 
6) Miyagawa, S et al : Impaired myocardium regeneration with skeletal cell sheets--a preclinical trial for tissue-engineered regeneration therapy. Transplantation 2010 ; 90 : 364-372
 
7) Miyagawa, S et al : Tissue-engineered cardiac constructs for cardiac repair. Ann Thorac Surg 2011 ; 91 : 320-329
 
8) Sawa, Y et al : Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease. Circ J 2015 ; 79 : 991-999
 
9) Yu, T et al : In vivo differentiation of induced pluripotent stem cell-derived cardiomyocytes. Circ J 2013 ; 77 : 1297-1306
 
10) Kawamura, M et al : Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012 ; 126 (11 Suppl 1) : S29-S37
 
11) Kawamura, M et al : Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation 2013 ; 128 (11 Suppl 1) : S87-S94
 
12) Matsuura, K et al : Elimination of remaining undifferentiated induced pluripotent stem cells in the process of human cardiac cell sheet fabrication using a methionine-free culture condition. Tissue Eng Part C Methods 2015 ; 21 : 330-338
 

書評

最近チェックした商品履歴

Loading...